Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C
Status:
Unknown status
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This trial is to determine the safety of valacyclovir in persons with chronic hepatitis C and
herpes simplex type 2 infection. Participants will be randomized to valacyclovir or matching
placebo. After receiving the initial therapy for eight weeks, the participants will cross
over to the alternate therapy for an additional eight weeks. Each treatment period will be
separated by a two-week period of daily placebo. The hypothesis is that treatment with
valacyclovir will result in a significant reduction in serum levels of hepatitis C virus
ribonucleic acid.